• PSA supports the proposal to publish the names of excipient ingredients in the ARTG. This will promote consumer access to relevant information which may be helpful in making informed decisions about their health care. We also note this approach is similar to arrangements in place in several countries.

• Of the two sub-options presented under Option 1, PSA’s preference is Option 1A: *Publish names of excipients except those used in flavour or fragrance proprietary ingredient mixes.* We note this sub-option provides a more comprehensive solution (compared to sub-option 1B).

• With regards to possible implementation, it is not clear from the consultation paper whether there is any action required of manufacturers who have products listed on the ARTG. PSA notes that full formulation details are (already) provided to, and held in, the ARTG – and that this information would now be added to their ARTG public summaries. If manufacturers will be required to undertake further action, PSA suggests it may be something that needs to be communicated to pharmacists who compound products that are listed on the ARTG. PSA seeks clarification of this matter. As the peak body for pharmacists, PSA is committed to working with the TGA to assist with timely dissemination of information to pharmacists, if required.